GlassScriptPhysician profile
Nayeem Karim
NPI 1073690079
$29,904.66
in general payments reported to CMS, 2019-2025
19 companies · $668 in 2025
The $668 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,504 · 2020: $7,756 · 2021: $2,794 · 2022: $6,292 · 2023: $4,480 · 2024: $410 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,960 · Food and Beverage: $1,489 · Education: $75.00 · Travel and Lodging: $33.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,960.00 |
| Food and Beverage | $1,489.32 |
| Education | $75.00 |
| Travel and Lodging | $33.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $27,329.44 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Irhythm Technologies, INC. | $378.78 | 2022-2023 | Zio Xt Patch |
| Neurelis, INC. | $364.13 | 2021-2024 | Valtoco |
| Livanova USA, INC. | $239.10 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $193.16 | 2022-2025 | |
| Biogen, INC. | $173.52 | 2021-2022 | |
| Allergan, INC. | $148.21 | 2019 | |
| Sk Life Science, INC. | $130.70 | 2022 | |
| Janssen Pharmaceuticals, INC | $124.32 | 2022 | |
| Eisai INC. | $121.36 | 2025 | |
| Abbvie INC. | $116.30 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $105.98 | 2021 | |
| Springworks Therapeutics, INC. | $104.86 | 2025 | Gomekli |
| Genzyme Corporation | $97.05 | 2020 | |
| Lilly USA, LLC | $91.10 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $75.00 | 2024 | Ultomiris |
| Promius Pharma LLC | $49.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.33 | 2019-2020 | |
| Abbott Laboratories | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayeem Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.